Retinal Physician – SUBSPECIALTY NEWS: A label change for Beovu, AI for AMD, clinical trial data, and more.

Warnings added regarding retinal vasculitis and retinal vascular occlusion. ■ Novartis has reported that the FDA approved a label update for Beovu (brolucizumab) to include additional safety information regarding retinal vasculitis and retinal vascular occlusion. This change follows the announcement by Novartis that it would pursue worldwide label updates after a review and further…